Examples of using Combination with ipilimumab in English and their translations into Swedish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Table 1: Recommended treatment modifications for OPDIVO or OPDIVO in combination with ipilimumab.
OPDIVO in combination with ipilimumab may cause changes in the results of tests carried out by your doctor.
The following side effects have been reported in clinical trials with nivolumab in combination with ipilimumab.
When OPDIVO is given in combination with ipilimumab, you will first be given OPDIVO followed by ipilimumab. .
nivolumab or nivolumab in combination with ipilimumab should be withheld.
Nivolumab or nivolumab in combination with ipilimumab is associated with immune-related adverse reactions.
The dose and frequency to be given depends on whether it is used alone or in combination with ipilimumab.
In patients treated with nivolumab in combination with ipilimumab, the incidence of rash was 63.4% 284/448.
colitis has been observed with nivolumab monotherapy or nivolumab in combination with ipilimumab see section 4.8.
When administered in combination with ipilimumab, OPDIVO should be given first followed by ipilimumab on the same day.
Severe hepatitis has been observed with nivolumab monotherapy or nivolumab in combination with ipilimumab see section 4.8.
In patients treated with nivolumab in combination with ipilimumab, the incidence of diarrhoea
nivolumab or nivolumab in combination with ipilimumab should be withheld.
Nivolumab in combination with ipilimumab should be discontinued for life-threatening
Severe infusion reactions have been reported in clinical trials of nivolumab or nivolumab in combination with ipilimumab see section 4.8.
Nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued for life-threatening(Grade 4) hypophysitis.
renal dysfunction have been observed with monotherapy treatment or nivolumab in combination with ipilimumab see section 4.8.
Upon improvement, nivolumab or nivolumab in combination with ipilimumab may be resumed after corticosteroid taper.
for patients treated with nivolumab in combination with ipilimumab(n=448) are presented in Table 2.
Upon improvement, nivolumab or nivolumab in combination with ipilimumab may be resumed after corticosteroid taper, if needed.
When OPDIVO is given in combination with ipilimumab the recommended dose of OPDIVO is 1 mg of nivolumab per kilogram of your body weight for the first 4 doses combination phase.
nivolumab or nivolumab in combination with ipilimumab should be withheld and corticosteroids administered.
The safety and efficacy of nivolumab in combination with ipilimumab or nivolumab vs. ipilimumab monotherapy for the treatment of advanced(unresectable
nivolumab or nivolumab in combination with ipilimumab should be withheld and corticosteroids administered.
Nivolumab or nivolumab in combination with ipilimumab should be withheld for Grade 3 rash and discontinued for Grade 4 rash.
Immune-related adverse reactions have occurred at higher frequencies when nivolumab was administered in combination with ipilimumab compared with nivolumab as monotherapy.
In patients treated with nivolumab in combination with ipilimumab, the incidence of nephritis
OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced(unresectable
Randomised phase 3 study of nivolumab in combination with ipilimumab or nivolumab as monotherapy vs. ipilimumab as monotherapy CA209067.
In patients treated with nivolumab in combination with ipilimumab, the incidence of liver function test abnormalities was 27.9% 125/448.